BioCentury | Jun 26, 2008
Cover Story

New Area in Malaria

Development of malaria therapeutics has been stymied by poor understanding of drug targets and limited corporate interest in picking up preclinical compounds with therapeutic promise. At the same time, the parasite has shown mounting resistance...
BioCentury | Apr 1, 2002
Product Development

Guidant spreading its stent bets

Guidant Corp. 's decision to license Novartis AG 's everolimus anti-proliferative compound for use in drug-eluting stents shouldn't be seen as a vote of no confidence in its Achieve paclitaxol-eluting stents, according to the company....
BioCentury | Mar 11, 2002
Clinical News

Actinomycin-D stent: Pilot

Data from the first 90 patients in GDT's pilot ACTION trial showed that the actinomycin-D stent was not effective in preventing restenosis. GDT said that patients treated with the stent had a high target lesion...
BioCentury | Mar 11, 2002

Ebb & Flow

The good news is that biotech almost kept pace with NASDAQ last week; the bad news is it has a ways to go to catch up with the composite on a year-to-date basis. The NASDAQ...
BioCentury | Mar 7, 2002
Clinical News

Guidant halts ACTION

GDT halted ACTION, a clinical trial of actinomycin-D eluting stent, after preliminary results showed that it was not effective in preventing restenosis. BC Staff...
Items per page:
1 - 5 of 5